and degeneration. 6 Cell death of photoreceptors in RP mouse models has been associated with a decrease in Bcl-2 and an increase in Bax proteins. 7 Although in recent decades, efforts have been made to identify the causative gene mutations for RP and to understand the molecular mechanisms that lead to photoreceptor degeneration, there are still no cure or effective therapies that can slow the progression of RP. 1 Rasagiline (N-propargyl-1 (R)-aminoindan) is a widely used antiparkinsonian drug that acts by inhibiting irreversibly and selectively monoamine oxidase B (MAO-B). 8 It is known that in a parkinsonian brain, the MAO-B levels are elevated, being responsible for an increase in oxidative stress and dopamine degradation. 9 At therapeutic doses (1 mg/d), rasagiline inhibits more than 90% of the MAO-B activity one to 3 weeks after starting the treatment 10 , and the MAO-B inhibition is maintained for more than a month after the treatment withdrawal. Additionally, rasagiline is able to suppress the oxidative effect associated with dopamine metabolism, which can induce cell death due to free radical formation. 11 However, some studies have
shown that its neuroprotective effect is not only related to MAO-B inhibitory activity. 10, 12 Within the neuroprotective effects of rasagiline, it has been found that it allows the conversion of the insoluble amyloid precursor protein (APP) into a soluble, neurotrophic and neuroprotective APP alpha, through protein kinase C (PKC) and MAP kinase-dependent activation of α-secretase. 13 Besides, it increases the expression of genes that regulate the production of glial cell line-derived neurotrophic factor and brainderived neurotrophic factor. These are known to promote neuroprotection in degenerative processes. 14 The neuroprotective effect of rasagiline has also been associated with a decrease in proapoptotic factors, such as Bax, and in an increase of antiapoptotic molecules, such as Bcl-2. 15, 16 It has been previously reported that rasagiline promotes retinal ganglion cell survival in a rat model of glaucoma, 17 as well as it delays photoreceptor degeneration in Prph2/rds model of RP. 18 In this new study, we proposed to test the neuroprotective effect of rasagiline in a well-characterized model of RP having a mutation in the Pde6b gene which endodes the rod cGMP-specific 3′,5′-cyclic phosphodiesterase subunit beta protein. The Pde6b rd10/rd10 (retinal degeneration 10; rd10) mouse displays a more severe phenotype than Prph2/rds mice. As photoreceptor degeneration is associated with an imbalance between proand antiapoptotic factors, we decided to test whether rasagiline could modulate the expression of Bax/Bcl-2 in rd10 mouse retinas. Visual function, electrical activity of mouse retinas, histology, and protein expression of different markers were evaluated in rasagiline-treated rd10 mice and its respective rd10 untreated controls. 
| MATERIALS AND METHODS

| Animal handling
| Rasagiline administration
Rasagiline (SML0124, Sigma Aldrich) at a final concentration of 15 μg/g body weight (BW)/d was diluted in water. During the first fourteen postnatal days, the drug was administered to the pups through breastmilk feeding, as previously described. 18, 19 In these two studies, it was shown that rasagiline is transferred through milk from nursing mothers to breastfed mice or rats, respectively, inhibiting MAO-B activity in whole-brain samples. After weaning, the drug was administered orally by water ingestion up to 1-month postnatal (P30) according to the protocol described by Eigeldinger-Berthou 18 with few modifications. Untreated rd10 mice were used as controls. The evaluation of rasagiline-treated and untreated rd10 mice was performed at P30.
| Optomotor test (OT)
Visual acuity was evaluated using the OptoMetry system (Cerebral the virtual cylinder at a constant distance. When the stripes of the cylinder started rotating (12 degrees/s), the mouse moved the head in the same direction of stripes rotation. The tracking movement produced by the stimulation of the stripes was considered as a positive response when the mouse's head followed the cylinder rotation, against the stationary arms of the star cursor. A negative response was considered when, after 5 seconds, no tracking movements were produced. To increase the sensitivity of the test, the observer was blind to treated and control group.
| Electroretinogram (ERG)
Full-field ERGs were performed as previously described by Valdes- 
| Immunofluorescence
The animals were euthanized by cervical dislocation at P30. The eyes were quickly excised and processed depending on the experi- 
| Photoreceptor nuclei counting
Transversal sections of untreated and rasagiline-treated rd10 mice were stained with hematoxylin and eosin. The number of nuclei across the outer nuclear layer (ONL) was determined in sections from five parallel series. The number of rows of photoreceptor nuclei was counted at the same positions: ±500, ±1000 and ±1500 μm from the optic nerve head. This included evaluation of the rod and cone nuclei.
| Western blot
The right eyes were enucleated, and the neural retinas and RPE were extracted by dissection of the eyeball. Proteins were extracted in ice-cold RIPA buffer containing protease and phosphatase in- and immunoreactive bands were detected by chemiluminescence using ECL plus (Amersham). Bcl-2 immunoreactive bands were quantified by densitometric analysis using ImageJ software, and normalized with GAPDH immunoreactive bands.
| Statistical analysis
The results are expressed as mean ± standard error of the mean (SEM). 
| RESULTS AND DISCUSSION
| Oral administration of rasagiline ameliorates visual dysfunction in rd10 mice
Rd10 mouse model harbors a spontaneous missense point mutation in the Pde6b gene which encodes for the β-subunit of phosphodiesterase 6 complex. This protein complex is essential for phototransduction and, in humans, PDE6B mutations cause autosomal recessive RP. 21 The rd10 mouse model exhibit a severe photoreceptor degeneration, primarily affecting the rods, starting at postnatal day 16 (P16), followed by cones in the later stages. The peak of rod cell death occurs between P21 and P25, and cone degeneration is completed at P60. and cone-rod ( Figure 2B ,E,H) responses at 1 and 3 cd.s/m 2 were higher in the animals subjected to rasagiline treatment ( Figure 2D ,E), when compared with the untreated animals ( Figure 2A,B) . These results show that electrical responses of rods are preserved in rd10-treated mice.
However, no differences were found in light-adapted b-wave of cone responses ( Figure 2C,F,I ). Although the expression of opsin is decreased at P30 in untreated rd10 mice (as showed in the Figure 4H ), the expression levels were enough to produce a cone response in the ERG and for these reason, no therapeutic effect was visible in the light-adapted b-wave cone responses at P30 ( Figure 2C,F,I ). We cannot discard the possibility of getting differences between control and treated animals in light-adapted b-wave of cone responses at P60, the time-point that is known that rd10 mice display a completely flat ERG signal for cone response. The OT and ERG results demonstrate that visual function and rod electrical responses were preserved in rasagiline-treated rd10 mice.
| Rasagiline treatment delays photoreceptor degeneration
To evaluate the neuroprotective effect of rasagiline in the retina, we counted the number of photoreceptor nuclei in six axes drawn perpendicular to the RPE and projected on the ONL at three different distances from the optic nerve (±500, ±1000 and ±1500 μm) ( Figure 3A) . Our results show that 1 month after treatment with rasagiline, there is a marked delay in photoreceptor degeneration, showed by an enhanced number of photoreceptor nuclei in the ONL ( Figure 3B ,C). The significant difference in the number of photoreceptors nuclei was more evident in the peripheral retina at ±1500 μm from the optic nerve ( Figure 3 ). This region of the retina is less exposed to light which can cause retinal damage in rd10 mice, 23 and probably for this reason, the neuroprotective effect of rasagiline on photoreceptors was more evident in this region of mouse retinas.
The neuroprotective effect of rasagiline treatment in rd10 mice is in agreement with the previously published results by EigeldingerBerthou 18 that showed a structural conservation of the ONL in Prph2/ rds mutant mice after rasagiline treatment. In that study, it was shown F I G U R E 3 Histogram of the photoreceptor nuclei counting in untreated rd10 (control) and rasagiline-treated rd10 mice. The number of photoreceptor nuclei was counted in the superior and inferior part of the retina at the same positions: ±500, ±1000, and ±1500 μm from the optic nerve head (A). Transversal sections of untreated (B) and rasagiline-treated (C) rd10 mice stained with hematoxylin and eosin. In the animals treated with rasagiline, the number of photoreceptors in the ONL is preserved (C). The results are expressed as mean ± SEM (N = 5 control, N = 6 rasagiline treated). Significant differences were determined using a two-way ANOVA and Uncorrected Fisher's LSD test. Pairwise comparison between groups and distance from the optic nerve head *P < 0.05; **P < 0.01; ***P < 0.001. GCL, Ganglion Cell Layer; INL, Inner Nuclear Layer; ONL, Outer Nuclear Layer; RPE, Retinal Pigment Epithelium. Scale bars represent 50 μm that a low-dose rasagiline treatment (2 μg/g BW/d) leads to photoreceptor cell protection on Prph2/rds mouse. 18 In our study, we have used
an intermediate dose between those tested by Eigeldinger-Berthou 18 that have not presented toxic effects. We decided to work with a higher dose (15 μg/g BW/d) because rd10 mice display more severe phenotype than Prph2/rds mice that is considered a slow-degeneration model of RP.
In Prph2/rds mice, photoreceptor degeneration starts 2-3 weeks after birth (P14-P21) and the ONL is completely degenerated at 9 months of age. 24 For this reason, in the study conducted by Eigeldinger-Berthou 18, the period of the treatment was 56 days. On the other hand, due to the severity of the rd10 phenotype, in which the peak of rod photoreceptors degeneration is at P21-P25, we have performed a short-term rasagiline treatment during only 30 days and using a higher dose.
The neuroprotective effect of rasagiline was also confirmed by immunofluorescence ( Figure 4A -F) and Western blot ( Figure 4G ,H).
We observed that the photoreceptor-specific markers rhodopsin and opsin were conserved in the retina of the rd10 mice treated with rasagiline ( Figure 4D -F) when compared with the rd10 untreated controls, in which less rhodopsin and opsin expression were detectable ( Figure 4A-C) . We observe a discrepancy between the immunofluorescence and Western blot results, in which the rhodopsin band was not detected in the untreated rd10 mice ( Figure 4G ), but a weak signal was observed in the immunofluorescence ( Figure 4A ). To confirm these results, we performed an immunofluorescence with the same rabbit antirhodopsin antibody used to perform the Western blot ( Figure S1d-g ). As expected, rhodopsin signal was not detected in untreated rd10 mice.
It is known that in rd10 mouse model, degeneration of cone photoreceptors is slower than rods. The degeneration of cones is complete at P60 and at P30 some cone photoreceptor cells remain in the ONL. 22 For these reason, we observed a band of opsin in rd10 untreated mice which were weaker than in the treated group ( Figure 4H) . Therefore, the results of photoreceptor nuclei counting and the persistency of photoreceptor markers prove that rasagiline has a therapeutic effect delaying photoreceptor degeneration in the rd10 mice, which is a faster retinal degeneration model than Prph2/rds. It is important to note that the protective effect of rasagiline seems to be independent of the gene mutation causing RP, because the rd10 and Prph2/rds are two completely different mutant mice. This might suggest that this drug could be a potential pan-therapeutic drug for RP.
| Rasagiline prevents photoreceptor apoptosis through Bcl-2 pathway
It is known that in rd10 retinas, the expression of proapoptotic factors, such as Bax is significantly increased, when compared with wild-type retinas. 25 This increase is intimately associated with photoreceptor degeneration. Moreover, several in vitro and in vivo studies have described that rasagiline modulates intracellular signaling pathways involved in cell death and survival through the 4, 15, 16, 26 To analyze the effect of rasagiline treatment in photoreceptor degeneration, retinal sections of rd10 mice treated with rasagiline and untreated ones were immunostaining with anti-Bax antibodies. In the untreated rd10 mice, high number of Bax-positive cells was visible ( Figure 5A ). Contrary, in the treated animals, almost no Bax staining was visible ( Figure 5B ). On the other hand, Bcl-2 signal was detected in the ONL of rasagilinetreated group ( Figure 5F ; arrows) but not in the untreated rd10 mice ( Figure 5E ). We also have evaluated the expression of Bcl-2 in the retina of the animals treated with rasagiline by Western blot ( Figure 5C ), and we found that there is a significant increase of Bcl-2 expression in the animals treated with rasagiline, when compared with the untreated ones ( Figure 5C,D) . These results reinforce the previously published results describing that rasagiline is able to increase BCL2 and reduce BAX gene expression. 15, 16, 26, 27 We still do not know whether Bcl-2 expression affects the mitochondrial permeability in photoreceptors of rd10 mice, but it is well established that high Bcl-2 expression prevents mitochondrial damage through PKC activation promoting cell survival. Immunofluorescence are representative images of nine different animals of three independent experiments (three rd10 untreated controls and 3 rasagiline rd10-treated mice for each experiment).
In the Western blotting to evaluate Bcl-2 expression, the GAPDH bands were used as loading control (C). The bars in the graph (D) represent the mean of Bcl-2/GAPDH ratio ± SEM (N = 3 control, N = 3 rasagiline treated from the same litters). Significant differences were determined using t test. *P < 0.05. GCL, Ganglion Cell Layer; INL, Inner Nuclear Layer; ONL, Outer Nuclear Layer; RPE, Retinal Pigment Epithelium. Scale bars represent 100 μm (A, B) and 50 μm (E, F)
